H1 operating losses increased by €1.1m to € -5.6m before research tax credits (+€1m). The net loss amounted to €4.9m (vs €3.9m). The clinical development plan is progressing according to expectations and could be expanded from 2016.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Increased R&D
Neovacs SA (0W8U:LON) | 0 0 0.4% | Mkt Cap: 32.4m
- Published:
06 Oct 2015 -
Author:
Armelle Moulin -
Pages:
2
H1 operating losses increased by €1.1m to € -5.6m before research tax credits (+€1m). The net loss amounted to €4.9m (vs €3.9m). The clinical development plan is progressing according to expectations and could be expanded from 2016.